Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?
Robert Leonard(National Cancer Centre Japan), Judith M. Bliss(Institute of Cancer Research), Alistair Ring(Brighton and Sussex Medical School), J Mansi(St Thomas' Hospital), Andreas Makris(Mount Vernon Cancer Centre), L. Johnson(Los Alamos National Laboratory), Peter Ellis(Wellcome Sanger Institute), Lucy Kilburn(Institute of Cancer Research), Malcolm Reed(Yorkshire Cancer Research), Peter Simmonds(Centre for Immunity, Infection and Evolution), Rachel Ballinger(Brighton and Sussex Medical School), Lesley Fallowfield(Brighton and Sussex Medical School), Margot Gosney(Royal Berkshire NHS Foundation Trust), Gerry Thomas(Imperial College London), A. Robinson(Southend Hospital), David Cameron(Edinburgh Cancer Research)
Cited by 50
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k